The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a CBD/THC combination treatment under its Named Patient programme and other compassionate areas.
Medlab’s NanaBis, to be used under NanaDol, a botanical version of NanaBis, has previously shown encouraging Phase I/II data for the treatment of cancer-induced bone pain and could be a potential alternative to opioids.
NanaDol will be available to patients in the UK through doctor prescription only for pain (including cancer-related bone pain). Medlab will be charging a ‘compassionate’ price (usually a discount to the expected list price), so we expect any additional revenue generated from compassionate use to be marginal.
The company hopes to generate additional real-world data to support an anticipated Phase III clinical trial of synthetic NanaBis in 2023. The trial will enroll patients at sites in the United States, UK and Australia.
Medlab is also developing NanoCBD, a 100% CBD formulation to treat occupational stress and mental health issues. NanoCBD received UK approval in April 2022 and it will be supplied through distribution partner WEP Clinical.